David Young, holding the dual roles of President of Research & Development and director at Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), has moved to increase his direct ownership in the company. On June 15, 2026, Mr. Young acquired 2,067 shares of common stock at a price of $2.22 per share. This transaction brought the total value of his purchase to $4,588.
Following the acquisition, Mr. Young's direct stake in Processa Pharmaceuticals stands at 19,198 shares. The current market price for the stock is $2.09, representing a slight discount to the price at which Mr. Young executed his purchase. Despite the current trading price being below the transaction level, the stock has exhibited a significant return over the last week, indicating recent upward momentum in the market.
According to analysis from InvestingPro, the stock appears to be trading below its calculated Fair Value estimate. This assessment has led to the stock's inclusion on the platform's list of Most Undervalued assets. The valuation data suggests that the market price may not fully reflect the underlying value of the company as determined by industry valuation models.
Beyond his direct holdings, Mr. Young maintains an indirect stake in Processa Pharmaceuticals through various affiliated entities. These indirect holdings include 1,242 shares held by the Young-Plaisance Revocable Trust, 432 shares held by Family Entities, and 1,009 shares held by CorLyst, LLC. The aggregation of direct and indirect holdings indicates a sustained level of interest in the company's equity from its senior leadership.
Market data also highlights the stock's performance characteristics. At the time of the report, the stock was closed at $2.09, reflecting a decline of $0.11 or 5.00%. However, after-hours trading showed a recovery, with the stock rising to $2.26, an increase of $0.17 or 8.13%. This volatility underscores the dynamic nature of the stock's recent trading activity.